Description

Tesamorelin 10mg Peptide Description

Tesamorelin 10mg is a research-grade synthetic peptide supplied as a lyophilized powder in a single vial, designed for in-vitro laboratory studies on growth hormone (GH) regulation, fat metabolism, and endocrine pathways. It is not approved for human or veterinary therapeutic use and is strictly intended for scientific research. The FDA-approved version (Egrifta SV® or Egrifta WR®) is a pharmaceutical formulation for specific clinical indications, but the 10mg vial format is commonly used in peptide research settings.

Composition

• Active Ingredient: Tesamorelin acetate, a 44-amino-acid analog of human growth hormone-releasing hormone (GHRH or GRF), with a trans-3-hexenoic acid modification at the N-terminal tyrosine for enhanced enzymatic stability and extended half-life compared to native GHRH.
• Purity: ≥99% as verified by HPLC and mass spectrometry (third-party COA recommended).
• Molecular Weight: Approximately 5,135 Da.
• Form: Lyophilized powder (freeze-dried) for stability; requires reconstitution with bacteriostatic water or sterile saline prior to use in experiments.
• Storage: -20°C in a desiccated environment; avoid repeated freeze-thaw cycles. Reconstituted solutions stable at 2-8°C for up to 14-28 days, depending on protocol.

The 10mg vial allows for precise dosing in research, typically yielding 10-20 doses at common concentrations (e.g., 1-2mg/mL post-reconstitution).

Mechanism of Action

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, mimicking endogenous GHRH to stimulate pulsatile GH secretion. This leads to downstream increases in insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) levels, promoting anabolic processes without direct GH administration. The hexenoyl modification protects against rapid dipeptidyl peptidase-4 (DPP-4) degradation, resulting in a longer duration of action (half-life ~26-38 minutes in plasma). In model systems, it supports fat lipolysis, particularly visceral adipose tissue reduction, while preserving natural GH-IGF-1 feedback loops.

Research Applications

Tesamorelin 10mg is widely studied in preclinical models for:

• Metabolic and Lipodystrophy Research: Reduction of visceral abdominal fat in HIV-associated lipodystrophy models; improves lipid profiles and insulin sensitivity.
• Growth and Recovery Pathways: Enhancement of lean muscle mass, bone density, and recovery from catabolic states via GH/IGF-1 axis activation.
• Endocrine and Aging Studies: Exploration of age-related GH decline, cognitive function, and cardiovascular health.
• Oncology and Safety Profiling: Assessment of potential tumorigenic risks, as elevated IGF-1 may promote cell proliferation in susceptible models.

Preclinical data from phase 3 trials (pooled analysis) show significant visceral adipose tissue (VAT) reduction (15-18% over 26 weeks) in HIV-lipodystrophy models, with neutral effects on subcutaneous fat. No long-term human trials exist for the isolated 10mg research form, and off-label use is not supported. Researchers should monitor for hypersensitivity or endocrine disruptions in vitro.

Research Protocols

• Reconstitution: Add 1-2mL bacteriostatic water to the 10mg vial for a 5-10mg/mL stock; gentle swirling (no shaking) to dissolve.
• Dosing: Typical in research: 1-2mg/day subcutaneously in animal models, administered once daily for 8-12 weeks to mimic clinical regimens. Adjust based on study endpoints (e.g., IGF-1 levels).
• Administration: Subcutaneous injection in rotating sites (abdomen, thigh) to minimize irritation; use insulin syringes for precision.
• Safety Notes: Contraindicated in models with active malignancy, pregnancy, or pituitary disorders. Monitor for injection-site reactions, arthralgia, or glucose elevations.

Always source from reputable suppliers with verifiable purity and adhere to biosafety protocols. For pharmaceutical-grade details, refer to FDA labeling.